Management and prognosis of patients with brain metastasis from gestational trophoblastic neoplasia: a 24-year experience in Peking union medical college hospital
Open Access
- 28 April 2015
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 318
Abstract
The optimal treatment for patients with brain metastasis from gestational trophoblastic neoplasia (GTN) has not been established. This study aims to investigate the clinical characteristics and the management of brain metastasis from GTN in relation to patients’ outcomes. We retrospectively investigated 109 GTN patients with brain metastasis treated at Peking Union Medical College Hospital from January 1990 to December 2013. Patients mainly received multiagent chemotherapy with florouracil or floxuridine, dactinomycin, etoposide, and vincristine (FAEV) combined with intrathecal methotrexate with or without surgery. In the 109 patients, sixty-two (56.1%) patients presented for primary therapy and 47 patients had failed chemotherapy elsewhere. Eight early demise patients who died before or during first cycle of chemotherapy were excluded from analysis. The median follow-up time was 47 months (range 9–180 months). The overall 5-year survival rate (OS) was 71.1%, while the OS rate for patients receiving primary chemotherapy in our hospital was 85.5%, and this fell to 51.9% in patients with failure multidrug chemotherapy elsewhere. Multivariate analysis demonstrated that International Federation of Gynecology and Obstetrics (FIGO) scores over 12 (Hazard ratio-HR 1.279, 95% CI 1.061-1.541, P = 0.010), failure of previous multidrug chemotherapy (HR 3.177, 95% CI 1.277-7.908, P = 0.013), and concurrent renal metastasis (HR 2.654, 95% CI 1.125-6.261, P = 0.026) were the risk factors of overall survival in patients with brain metastases from GTN. Patients with brain metastasis from GTN have favorable outcome by multidrug chemotherapy and adjuvant therapies. Nevertheless, the prognosis is poor if the patients had previous multidrug failure chemotherapy history, concomitant with renal metastasis, or FIGO score over 12. Initial treatment with FAEV combined with intrathecal methotrexate chemotherapy can bring bright prospect to patients with brain metastases from GTN.Keywords
This publication has 33 references indexed in Scilit:
- Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasiaGynecologic Oncology, 2012
- Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasiaAnnals of Oncology, 2011
- High-risk gestational trophoblastic neoplasia with brain metastases: Individualized multidisciplinary therapy in the management of four patientsGynecologic Oncology, 2007
- The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumoursBritish Journal of Cancer, 2006
- Evaluation and management of brain metastatic patients with high-risk gestational trophoblastic tumorsInternational Journal of Gynecological Cancer, 2004
- The practicability of FIGO 2000 staging for gestational trophoblastic neoplasiaInternational Journal of Gynecological Cancer, 2004
- EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV)International Journal of Gynecological Cancer, 2004
- Prognosis of Patients Treated with Whole-Brain Radiation Therapy for Metastatic Gestational Trophoblastic DiseaseGynecologic Oncology, 1998
- Gestational trophoblastic disease with liver metastases: the Charing Cross experienceBJOG: An International Journal of Obstetrics & Gynaecology, 1997
- Gestational Trophoblastic Disease Metastatic to the Central Nervous SystemGynecologic Oncology, 1995